These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 21371447)
21. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000. Smolka AJ; Goldenring JR; Gupta S; Hammond CE BMC Gastroenterol; 2004 Feb; 4():4. PubMed ID: 15028114 [TBL] [Abstract][Full Text] [Related]
22. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Scott DR; Munson KB; Marcus EA; Lambrecht NW; Sachs G Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1315-26. PubMed ID: 26423447 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of acid secretion by the nonsteroidal anti-inflammatory drugs diclofenac and piroxicam in isolated gastric glands: analysis of a multifocal mechanism. Salvatella M; Rossi I; Del Valle JC; Gutiérrez Y; Pereda C; Samper B; Felíu JE Am J Physiol Gastrointest Liver Physiol; 2004 May; 286(5):G711-21. PubMed ID: 14693505 [TBL] [Abstract][Full Text] [Related]
24. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418 [TBL] [Abstract][Full Text] [Related]
25. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Echizen H Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775 [TBL] [Abstract][Full Text] [Related]
27. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. Avner DL; Movva R; Nelson KJ; McFarland M; Berry W; Erfling W Am J Gastroenterol; 1995 Aug; 90(8):1289-94. PubMed ID: 7639232 [TBL] [Abstract][Full Text] [Related]
28. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. Florent C Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399 [TBL] [Abstract][Full Text] [Related]
29. Soraprazan: setting new standards in inhibition of gastric acid secretion. Simon WA; Herrmann M; Klein T; Shin JM; Huber R; Senn-Bilfinger J; Postius S J Pharmacol Exp Ther; 2007 Jun; 321(3):866-74. PubMed ID: 17369284 [TBL] [Abstract][Full Text] [Related]
30. Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa. Matsukawa J; Kogame A; Tagawa Y; Inatomi N Dig Dis Sci; 2016 Jul; 61(7):1888-94. PubMed ID: 26961787 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-93. Mamiya N; Goldenring JR; Tsunoda Y; Modlin IM; Yasui K; Usuda N; Ishikawa T; Natsume A; Hidaka H Biochem Biophys Res Commun; 1993 Sep; 195(2):608-15. PubMed ID: 7690557 [TBL] [Abstract][Full Text] [Related]
32. Treatment of patients with Zollinger-Ellison syndrome. Mignon M; Pospai D; Forestier S; Vatier J; Vallot T Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592 [TBL] [Abstract][Full Text] [Related]
33. [Lansoprazole--profile of a new proton pump inhibitor]. Seifert E Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467 [TBL] [Abstract][Full Text] [Related]
34. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. Shin JM; Cho YM; Sachs G J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527 [TBL] [Abstract][Full Text] [Related]
35. [Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate]. Matsukawa J; Inatomi N; Nishida H; Tsukimi Y Nihon Yakurigaku Zasshi; 2018; 152(3):104-110. PubMed ID: 30185727 [TBL] [Abstract][Full Text] [Related]
36. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease. Kim DK; Lee KH; Kim SJ; Kim SJ; Lee SJ; Park CH; Kim BT; Song GS; Moon BS; Ryu SY J Pharmacol Exp Ther; 2019 Jun; 369(3):318-327. PubMed ID: 30894456 [TBL] [Abstract][Full Text] [Related]
37. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. Takahashi N; Take Y J Pharmacol Exp Ther; 2018 Feb; 364(2):275-286. PubMed ID: 29180359 [TBL] [Abstract][Full Text] [Related]
38. Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action. Nishida H; Arikawa Y; Hirase K; Imaeda T; Inatomi N; Hori Y; Matsukawa J; Fujioka Y; Hamada T; Iida M; Nishitani M; Imanishi A; Fukui H; Itoh F; Kajino M Bioorg Med Chem; 2017 Jul; 25(13):3298-3314. PubMed ID: 28442261 [TBL] [Abstract][Full Text] [Related]
39. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Jenkins H; Sakurai Y; Nishimura A; Okamoto H; Hibberd M; Jenkins R; Yoneyama T; Ashida K; Ogama Y; Warrington S Aliment Pharmacol Ther; 2015 Apr; 41(7):636-48. PubMed ID: 25707624 [TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of novel 5-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives as potent potassium-competitive acid blockers. Wang X; Xu Y; Zong Z; Cai J; Chen C; Zhang Q; Sun X; Li J Bioorg Med Chem; 2022 Jun; 64():116765. PubMed ID: 35477061 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]